Nikita Zakharov

Mr. Nikita Zakharov

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YBYuliya Bortnevskaya
Yuliya Bortnevskaya
NSNikita A. Shiryaev
Nikita A. Shiryaev
NZNikita Zakharov
Nikita Zakharov
OKOleg O. Kitoroage
Oleg O. Kitoroage
MGMargaret Gradova
Margaret Gradova
KZKseniya A. Zhdanova
Kseniya A. Zhdanova
Photodynamic therapy (PDT) in oncology is characterized by low invasiveness, minimal side effects, and little tissue scarring. Increasing the selectivity of PDT agents toward a cellular target is a new approach intended to improve this method. This study is devoted to the design and synthesis of a new conjugate based on meso-arylporphyrin with a low-molecular-weight tyrosine kinase inhibitor, Erlotinib. A nano-formulation based on Pluronic F127 micelles was obtained and characterized. The photophysical and photochemical properties and biological activity of the studied compounds and their nano-formulation were studied. A significant, 20–40-fold difference between the dark and photoinduced activity was achieved for the conjugate nanomicelles. After irradiation, the studied conjugate nanomicelles were 1.8 times more toxic toward the EGFR-overexpressing cell line MDA-MB-231 compared to the conditionally normal NKE cells. The IC50 was 0.073 ± 0.014 μM for the MDA-MB-231 cell line and 0.13 ± 0.018 μM for NKE cells after irradiation for the target conjugate nanomicelles.